Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Renal Cell Carcinoma | Access and Reimbursement | US | 2018

Login to access report north_east
Contact sales account_box

MARKET OUTLOOK

Two of the largest U.S. pharmacy benefit managers, Express Scripts and CVS Health, set in motion a new approach to drug reimbursement by introducing indication-specific pricing (ISP). Instead of reimbursing a drug the same way across all indications for which it is approved, the PBMs have set up programs to vary reimbursement and formulary placement of some drugs based on their clinical value in different indications or patient subpopulations. This study examines the potential for this strategy to take hold with U.S. managed care organizations’ coverage of oncology drugs. Payers are surveyed about the potential for using an ISP strategy with drugs to treat renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), while oncologists are queried on their receptivity to this game-changing strategy.

QUESTIONS ANSWERED

  • What is the current access and prescribing landscape for RCC and HCC as new label expansions create more treatment alternatives?
  • What is the future for ISP in oncology and are MCOs employing this strategy now?
  • What are or will be the major challenges to varying pricing and/or coverage by indication and how do/will MCOs track diagnosis to implement ISP?
  • Do oncologists ever encounter situations where the drugs they prescribe are covered differently by indication, and what is their reaction to this trend?

PRODUCT DESCRIPTION Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (including IBS without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by altered bowel motility, stool consistency, and frequency, and is classified into constipation-predominant,…
north_east
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Breast Cancer (US)
The increasing focus on biomarkers has reshaped the treatment paradigm in oncology, allowing physicians to tailor treatments to subpopulations of patients diagnosed with breast cancer, NSCLC and…
north_east
Report
Spinal Muscular Atrophy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle weakness and is a leading genetic cause of death in infants. SMA is divided into four clinical subtypes…
north_east
Report
Crohn’s Disease – Access & Reimbursement – Access & Reimbursement – Crohn’s Disease (US)
TNF-α inhibitors, such as J&J Innovative Medicine’s Remicade and AbbVie’s Humira, remain firmly established in the U.S. Crohn’s disease (CD) treatment landscape. However, therapies with…
north_east
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east